Archives
Actin–Myosin II Network in DEV Infection: Proteomic Insights
2026-04-17
Understanding the Actin–Myosin II Network’s Role in Duck Enteritis Virus Replication
Study Background and Research Question
Duck enteritis virus (DEV) is the causative agent of duck viral enteritis, a highly contagious and lethal disease affecting waterfowl populations worldwide. Despite extensive investigation into DEV’s genetic and structural components, the specific host factors and molecular pathways commandeered by the virus during infection have remained largely undefined. An urgent need exists to clarify these host-pathogen interactions, both to inform therapeutic strategies and to deepen understanding of cytoskeletal dynamics in viral pathogenesis (Chen et al., 2025).Key Innovation from the Reference Study
The referenced study delivers a significant advance by employing a proteomic approach to map the interactome of DEV protein VP26 within infected chicken embryo fibroblast cells. Using recombinant rVP26-Flag and co-immunoprecipitation coupled with liquid chromatography–tandem mass spectrometry (Co-IP-MS/MS), the authors systematically identified 17 host proteins interacting with VP26. Notably, many of these proteins are cytoskeletal components—particularly actin filament-associated proteins and non-muscle myosin II (MYH9)—illuminating the centrality of the actin–myosin II network in DEV’s life cycle (Chen et al., 2025).Methods and Experimental Design Insights
The study's workflow began with the generation of a recombinant DEV expressing a Flag-tagged VP26 protein. Infected chicken embryo fibroblast cells were lysed and subjected to co-immunoprecipitation using anti-Flag antibodies to isolate protein complexes containing VP26. The protein complexes were then analyzed using LC-MS/MS to identify interacting host proteins. Importantly, the authors further validated selected interactions—specifically between VP26 and the carboxyl-terminus of MYH9 (amino acids 1651–1960)—using both co-immunoprecipitation and co-localization assays. To probe the functional relevance of these interactions, the researchers utilized small-molecule inhibitors of actin polymerization, including cytochalasin D and Latrunculin A, as well as siRNA-mediated knockdown of MYH9 and pharmacological inhibition of myosin II ATPase activity with (-)-Blebbistatin. Viral titers were quantified following these interventions to assess impact on DEV proliferation (Chen et al., 2025).Core Findings and Why They Matter
The proteomic screen identified 17 host proteins as putative VP26 interactors, with a notable enrichment for cytoskeletal and actin-binding proteins such as Xirp1, TMOD3, MYO5A, GSN, and particularly MYH9. Functional network analysis highlighted that these proteins cluster within the actin–myosin II cytoskeletal system. The most striking functional validation came from experiments disrupting this network:- Both Latrunculin A and cytochalasin D—reversible inhibitors of actin assembly—significantly reduced DEV titers in infected cells (source: paper).
- siRNA knockdown of MYH9 led to decreased viral proliferation, implicating MYH9’s ATPase activity in the viral life cycle (source: paper).
- Pharmacological inhibition of myosin II with (-)-Blebbistatin suppressed DEV infection both in vitro and in vivo (source: paper).
Protocol Parameters
- in vitro actin cytoskeleton disruption assay | Latrunculin A, 1–10 μM, 10 min to overnight | tumor cells, primary fibroblasts | Rapid, reversible induction of cytoskeleton disaggregation; robust inhibition of actin polymerization | product_spec
- viral infection model (DEV) | Latrunculin A, 5 μM, 2–4 h pre/post infection | chicken embryo fibroblasts | Reduced DEV titer; confirms actin polymerization required for viral proliferation | paper
- siRNA knockdown | MYH9-targeting siRNA, 10–50 nM, 48 h transfection | chicken embryo fibroblasts | Demonstrates MYH9’s essential role in DEV life cycle | paper
- myosin II ATPase inhibition | (-)-Blebbistatin, 10 μM, 16–24 h | in vitro and in vivo | Suppresses DEV infection by targeting myosin II function | paper
- workflow suggestion: cytoskeleton disaggregation screening | Latrunculin A, 1–10 μM, 10–60 min | multiple cell types | Enables rapid, reversible modulation of actin network for mechanistic studies | workflow_recommendation
Comparison with Existing Internal Articles
A number of internal resources provide complementary context for the use of Latrunculin A in cell biology and cytoskeletal research. For example, "Latrunculin A: Precision Actin Polymerization Inhibitor" highlights the compound’s gold-standard status as a reversible inhibitor of actin assembly, emphasizing its value in studies spanning tumor cell cytoskeleton disaggregation to viral pathogenesis. The current reference study extends these principles, directly demonstrating Latrunculin A’s utility in probing the cytoskeleton’s role in viral infection models. Additionally, "Latrunculin A as a Precision Tool for Actin Cytoskeleton" discusses the broader implications of targeting the actin–myosin II network in translational research. The proteomic evidence from Chen et al. (2025) provides mechanistic validation for such approaches, specifically in the context of DEV and related herpesviruses.Limitations and Transferability
While the referenced study robustly demonstrates the actin–myosin II network’s importance for DEV proliferation in chicken embryo fibroblast cells, several limitations should be considered:- Cell Type and Species: Findings are currently restricted to avian cells; extrapolation to other species or human herpesviruses requires direct testing.
- In Vivo Complexity: Although (-)-Blebbistatin was tested in vivo, Latrunculin A was not, so in vivo applicability of actin disaggregation remains to be established (source: paper).
- Protein Interactions: Not all 17 VP26-interacting proteins were functionally validated, leaving open questions about their individual contributions.